|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
H-cadherin (CDH13), protocadherin-10 (PCDH10), P-cadherin (CDH3), and M-cadherin (CDH15) methylation may have an increased risk of HCC in fewer than 4 studies, and methylated cadherin 8, type 2 (CDH8) and OB-cadherin (CDH11) had a similar OR in HCC and adjacent samples.
|
28422868 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.350 |
PosttranslationalModification
|
disease |
BEFREE |
Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines.
|
18553387 |
2008 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
To provide a functional link between T-cadherin promoter methylation and T-cadherin growth regulation, we used the HepG2 hepatoma cell line that exhibits T-cadherin promoter methylation.
|
18425332 |
2008 |
|
Liver carcinoma
|
0.350 |
PosttranslationalModification
|
disease |
LHGDN |
To provide a functional link between T-cadherin promoter methylation and T-cadherin growth regulation, we used the HepG2 hepatoma cell line that exhibits T-cadherin promoter methylation.
|
18425332 |
2008 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Upon pharmacological treatment with demethylating agent 5-aza-2'-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines.
|
18553387 |
2008 |
|
Liver carcinoma
|
0.350 |
PosttranslationalModification
|
disease |
BEFREE |
In the HCC with T-cadherin promoter methylation, the T-cadherin expression was significantly decreased compared to HCC without methylation.
|
18425332 |
2008 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
LHGDN |
An adiponectin receptor, T-cadherin, was selectively expressed in intratumoral capillary endothelial cells in hepatocellular carcinoma: possible cross talk between T-cadherin and FGF-2 pathways.
|
16273386 |
2006 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
LHGDN |
Expression of T-cadherin in tumor cells influences invasive potential of human hepatocellular carcinoma.
|
17077306 |
2006 |
|
Substance Use Disorders
|
0.330 |
GeneticVariation
|
group |
BEFREE |
Genome-wide association studies in humans have suggested that variants of the cadherin-13 (CDH13) gene are associated with substance use disorder, subjective response to amphetamine, and attention deficit hyperactivity disorder.
|
28387990 |
2017 |
|
Substance Use Disorders
|
0.330 |
GeneticVariation
|
group |
BEFREE |
A total of 110 adult patients with ASD (n=61) or ADHD (n=49) with or without a lifetime history of SUD participated in a study in which we genotyped polymorphisms in five known candidate genes for (one of) the disorders, i.e. the 5HTTLPR in SLC6A4/5-HTT, rs1800497 (TaqIA C>T) in DRD2, rs7794745 in CNTNAP2, rs1843809 in TPH2, and rs6565113 in CDH13.
|
20446882 |
2010 |
|
Substance Use Disorders
|
0.330 |
Biomarker
|
group |
CTD_human |
Genome wide association for addiction: replicated results and comparisons of two analytic approaches.
|
20098672 |
2010 |
|
Substance Use Disorders
|
0.330 |
Biomarker
|
group |
BEFREE |
CDH13 has been implicated previously in substance use disorders.
|
18821565 |
2008 |
|
Alcoholic Intoxication, Chronic
|
0.320 |
Biomarker
|
disease |
BEFREE |
For example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
|
22765916 |
2012 |
|
Alcoholic Intoxication, Chronic
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Genes that have been previously associated with depression, AD, or other addiction-related phenotypes - such as CDH13, CSMD2, GRID1, and HTR1B - were implicated by nominally significant SNPs.
|
22064162 |
2012 |
|
Alcoholic Intoxication, Chronic
|
0.320 |
Biomarker
|
disease |
PSYGENET |
For example, CDH15 and PCDH19 are associated with cognitive impairment; CDH5, CDH8, CDH9, CDH10, CDH13, CDH15, PCDH10, PCDH19 and PCDHb4 with autism; CDH7, CDH12, CDH18, PCDH12 and FAT with bipolar disease and schizophrenia; and CDH11, CDH12 and CDH13 with methamphetamine and alcohol dependency.
|
22765916 |
2012 |
|
Alcoholic Intoxication, Chronic
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Nine SNPs were located in genes, including the CDH13 and ADH1C genes, that have been reported to be associated with alcohol dependence.
|
19581569 |
2009 |
|
Alcoholic Intoxication, Chronic
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Nine SNPs were located in genes, including the CDH13 and ADH1C genes, that have been reported to be associated with alcohol dependence.
|
19581569 |
2009 |
|
Mental Depression
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CDH13 is upregulated by chronic stress as well as in depression, suggesting a role in early-life adaptation to stressful experience.
|
30165120 |
2019 |
|
Depressive disorder
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, CDH13 is upregulated by chronic stress as well as in depression, suggesting a role in early-life adaptation to stressful experience.
|
30165120 |
2019 |
|
Esophageal Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
RESULTS Compared with adjacent normal tissues, the methylation frequencies of WIF-1, RASSF1A, and CDH13 genes were significantly higher but the mRNA levels of these 3 genes were significantly lower in EC tissues (all P<0.05).
|
27506957 |
2016 |
|
Malignant neoplasm of esophagus
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Compared with adjacent normal tissues, the methylation frequencies of WIF-1, RASSF1A, and CDH13 genes were significantly higher but the mRNA levels of these 3 genes were significantly lower in EC tissues (all P<0.05).
|
27506957 |
2016 |
|
Substance abuse problem
|
0.310 |
Biomarker
|
disease |
BEFREE |
No substantial signal was observed for either MAOA or CDH13 among non-violent offenders, indicating that findings were specific for violent offending, and not largely attributable to substance abuse or antisocial personality disorder.
|
25349169 |
2015 |
|
Malignant neoplasm of prostate
|
0.310 |
PosttranslationalModification
|
disease |
BEFREE |
Promoter methylation of CDH13 occurred frequently in the serum of patients with prostate cancer, was associated with an increased risk of death, and may become a useful independent predictor of a poor prognosis.
|
25015764 |
2014 |
|
Mental Depression
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Genes that have been previously associated with depression, AD, or other addiction-related phenotypes - such as CDH13, CSMD2, GRID1, and HTR1B - were implicated by nominally significant SNPs.
|
22064162 |
2012 |